Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
- PMID: 31774955
- PMCID: PMC7098487
- DOI: 10.1056/NEJMoa1905795
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus
Abstract
Background: The choice of drugs for patients with status epilepticus that is refractory to treatment with benzodiazepines has not been thoroughly studied.
Methods: In a randomized, blinded, adaptive trial, we compared the efficacy and safety of three intravenous anticonvulsive agents - levetiracetam, fosphenytoin, and valproate - in children and adults with convulsive status epilepticus that was unresponsive to treatment with benzodiazepines. The primary outcome was absence of clinically evident seizures and improvement in the level of consciousness by 60 minutes after the start of drug infusion, without additional anticonvulsant medication. The posterior probabilities that each drug was the most or least effective were calculated. Safety outcomes included life-threatening hypotension or cardiac arrhythmia, endotracheal intubation, seizure recurrence, and death.
Results: A total of 384 patients were enrolled and randomly assigned to receive levetiracetam (145 patients), fosphenytoin (118), or valproate (121). Reenrollment of patients with a second episode of status epilepticus accounted for 16 additional instances of randomization. In accordance with a prespecified stopping rule for futility of finding one drug to be superior or inferior, a planned interim analysis led to the trial being stopped. Of the enrolled patients, 10% were determined to have had psychogenic seizures. The primary outcome of cessation of status epilepticus and improvement in the level of consciousness at 60 minutes occurred in 68 patients assigned to levetiracetam (47%; 95% credible interval, 39 to 55), 53 patients assigned to fosphenytoin (45%; 95% credible interval, 36 to 54), and 56 patients assigned to valproate (46%; 95% credible interval, 38 to 55). The posterior probability that each drug was the most effective was 0.41, 0.24, and 0.35, respectively. Numerically more episodes of hypotension and intubation occurred in the fosphenytoin group and more deaths occurred in the levetiracetam group than in the other groups, but these differences were not significant.
Conclusions: In the context of benzodiazepine-refractory convulsive status epilepticus, the anticonvulsant drugs levetiracetam, fosphenytoin, and valproate each led to seizure cessation and improved alertness by 60 minutes in approximately half the patients, and the three drugs were associated with similar incidences of adverse events. (Funded by the National Institute of Neurological Disorders and Stroke; ESETT ClinicalTrials.gov number, NCT01960075.).
Copyright © 2019 Massachusetts Medical Society.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7098487/bin/nihms-1565235-f0001.gif)
![Figure 2.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/7098487/bin/nihms-1565235-f0002.gif)
Comment in
-
Management of Established Status Epilepticus.N Engl J Med. 2019 Nov 28;381(22):2171-2172. doi: 10.1056/NEJMe1913775. N Engl J Med. 2019. PMID: 31774965 No abstract available.
-
Second-line anticonvulsant for convulsive status epilepticus: The dosage matters!Anaesth Crit Care Pain Med. 2020 Feb;39(1):11-13. doi: 10.1016/j.accpm.2019.12.007. Epub 2020 Jan 2. Anaesth Crit Care Pain Med. 2020. PMID: 31904430 No abstract available.
-
[Focus neurological intensive care medicine : Intensive medical care studies from 2019/2020].Anaesthesist. 2021 Feb;70(2):164-170. doi: 10.1007/s00101-020-00861-z. Anaesthesist. 2021. PMID: 33051691 Free PMC article. German. No abstract available.
-
Comparison of three anticonvulsive agents for benzodiazepine resistant status epilepticus.CJEM. 2021 Jan;23(1):29-31. doi: 10.1007/s43678-020-00021-7. Epub 2020 Dec 10. CJEM. 2021. PMID: 33683605 No abstract available.
Similar articles
-
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.Lancet. 2020 Apr 11;395(10231):1217-1224. doi: 10.1016/S0140-6736(20)30611-5. Epub 2020 Mar 20. Lancet. 2020. PMID: 32203691 Free PMC article. Clinical Trial.
-
Treatment of Toxin-Related Status Epilepticus With Levetiracetam, Fosphenytoin, or Valproate in Patients Enrolled in the Established Status Epilepticus Treatment Trial.Ann Emerg Med. 2022 Sep;80(3):194-202. doi: 10.1016/j.annemergmed.2022.04.020. Epub 2022 Jun 17. Ann Emerg Med. 2022. PMID: 35718575 Clinical Trial.
-
Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT.Health Technol Assess. 2020 Nov;24(58):1-96. doi: 10.3310/hta24580. Health Technol Assess. 2020. PMID: 33190679 Free PMC article. Clinical Trial.
-
Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.Seizure. 2022 Nov;102:74-82. doi: 10.1016/j.seizure.2022.09.017. Epub 2022 Sep 26. Seizure. 2022. PMID: 36209676 Review.
-
A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children.Expert Rev Neurother. 2022 Jan;22(1):1-13. doi: 10.1080/14737175.2021.2001328. Epub 2021 Dec 19. Expert Rev Neurother. 2022. PMID: 34726961 Review.
Cited by
-
Assessment of cerebral drug occupancy in humans using a single PET-scan: A [11C]UCB-J PET study.Eur J Nucl Med Mol Imaging. 2024 May 17. doi: 10.1007/s00259-024-06759-x. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38758370
-
Risk assessment of arrhythmias related to three antiseizure medications: a systematic review and single-arm meta-analysis.Front Neurol. 2024 Feb 14;15:1295368. doi: 10.3389/fneur.2024.1295368. eCollection 2024. Front Neurol. 2024. PMID: 38419702 Free PMC article.
-
Anti-epileptic drug (AED) loading in status epilepticus: an audit and introduction of levetiracetam loading protocol.Future Healthc J. 2023 Nov;10(Suppl 3):129-130. doi: 10.7861/fhj.10-3-s129. Future Healthc J. 2023. PMID: 38406728 Free PMC article. No abstract available.
-
An Expected Score Approach to Ordinal Outcomes in a Bayesian, Response Adaptive, Randomized Trial.Stat Biopharm Res. 2023;15(4):820-825. doi: 10.1080/19466315.2023.2169344. Epub 2023 Feb 24. Stat Biopharm Res. 2023. PMID: 38361772 Free PMC article.
-
Comparison of induction agents for rapid sequence intubation in refractory status epilepticus: A single-center retrospective analysis.Epilepsy Behav Rep. 2024 Jan 8;25:100645. doi: 10.1016/j.ebr.2024.100645. eCollection 2024. Epilepsy Behav Rep. 2024. PMID: 38299124 Free PMC article.
References
-
- Alldredge BK, Gelb AM, Isaacs SM, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345:631–7. - PubMed
-
- Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs diazepam for pediatric status epilepticus: a randomized clinical trial. JAMA 2014; 311: 1652–60. - PubMed
-
- Cook AM, Castle A, Green A, et al. Practice variations in the management of status epilepticus. Neurocrit Care 2012; 17: 24–30. - PubMed
-
- Riviello JJ Jr, Claassen J, LaRoche SM, et al. Treatment of status epilepticus: an international survey of experts. Neurocrit Care 2013; 18: 193–200. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- U01 NS073476/NS/NINDS NIH HHS/United States
- U01NS088023/NS/NINDS NIH HHS/United States
- U01 NS059041/NS/NINDS NIH HHS/United States
- U01 NS056975/NS/NINDS NIH HHS/United States
- U10 NS080369/NS/NINDS NIH HHS/United States
- U24 NS100651/NS/NINDS NIH HHS/United States
- U01NS059041/NS/NINDS NIH HHS/United States
- U01 NS088023/NS/NINDS NIH HHS/United States
- U01NS073476/NS/NINDS NIH HHS/United States
- U01NS088034/NS/NINDS NIH HHS/United States
- U01NS056975/NS/NINDS NIH HHS/United States
- U01 NS088034/NS/NINDS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical